The development of levofloxacin-bonded albumin dacron graft

Katsuhiro Fujimoto, Tsunehisa Sakurai, Keiko Yamamura, Takashi Osada, Tetsuo Hayashi, Kunihiko Koyasu, Toshitaka Nabeshima

Research output: Contribution to journalArticle

Abstract

The highly porous Dacron graft fabricated from polyester filaments is generally considered to be one of the most suitable synthetic vascular prostheses in arterial reconstructive surgery. To prevent blood leakage through the pores during an operation, several sealing materials such as albumin (ALB), collagen and gelatin have been employed. As vascular graft infection is a disastrous complication on vascular surgery, great effort must be taken to avoid it. To reduce the systemic effect while maintaining an increase in local resistance to graft infection, it seems reasonable that an antibiotic-loaded graft prolongs the release of antibiotics from the graft at the operated site. Common skin microorganisms, such as Staphylococcus aureus and Staphylococcus epidermidis, have been associated with graft-related infection. Levofloxacin (LVFX) was used as a model drug since it shows a broad protective spectrum against Gram-positive and Gram-negative bacteria, particularly staphylococci. To control the release rate of LVFX, ALB was bonded to the Dacron graft. In vitro and in vivo studies demonstrated that the release rate of LVFX decreased in the presence of ALB. One LVFX-ALB disk (diameter : 1.2 cm) was implanted in the skin pocket made in a rat, and inoculated with Staphylococcus aureus or Staphylococcus epidermidis (0.1 ml of 108 CFU/ml). While all control grafts were infected at the time of removal, all LVFX-ALB Dacron grafts resisted infection, thus demonstrating their effectiveness. These studies suggest that LVFX controlled-releasing Dacron delivery system can decrease graft infection at the operated site.

Original languageEnglish
Pages (from-to)345-349
Number of pages5
JournalDrug Delivery System
Volume11
Issue number5
DOIs
Publication statusPublished - 01-01-1996

Fingerprint

Levofloxacin
Polyethylene Terephthalates
Albumins
Transplants
Infection
Staphylococcus epidermidis
Blood Vessels
Staphylococcus aureus
Reconstructive Surgical Procedures
Blood Vessel Prosthesis
Anti-Bacterial Agents
Skin
Polyesters
Gelatin
Gram-Negative Bacteria
Staphylococcus
Collagen

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Fujimoto, K., Sakurai, T., Yamamura, K., Osada, T., Hayashi, T., Koyasu, K., & Nabeshima, T. (1996). The development of levofloxacin-bonded albumin dacron graft. Drug Delivery System, 11(5), 345-349. https://doi.org/10.2745/dds.11.345
Fujimoto, Katsuhiro ; Sakurai, Tsunehisa ; Yamamura, Keiko ; Osada, Takashi ; Hayashi, Tetsuo ; Koyasu, Kunihiko ; Nabeshima, Toshitaka. / The development of levofloxacin-bonded albumin dacron graft. In: Drug Delivery System. 1996 ; Vol. 11, No. 5. pp. 345-349.
@article{2ee6a5a5c3bc4bb89f02de592bbe0134,
title = "The development of levofloxacin-bonded albumin dacron graft",
abstract = "The highly porous Dacron graft fabricated from polyester filaments is generally considered to be one of the most suitable synthetic vascular prostheses in arterial reconstructive surgery. To prevent blood leakage through the pores during an operation, several sealing materials such as albumin (ALB), collagen and gelatin have been employed. As vascular graft infection is a disastrous complication on vascular surgery, great effort must be taken to avoid it. To reduce the systemic effect while maintaining an increase in local resistance to graft infection, it seems reasonable that an antibiotic-loaded graft prolongs the release of antibiotics from the graft at the operated site. Common skin microorganisms, such as Staphylococcus aureus and Staphylococcus epidermidis, have been associated with graft-related infection. Levofloxacin (LVFX) was used as a model drug since it shows a broad protective spectrum against Gram-positive and Gram-negative bacteria, particularly staphylococci. To control the release rate of LVFX, ALB was bonded to the Dacron graft. In vitro and in vivo studies demonstrated that the release rate of LVFX decreased in the presence of ALB. One LVFX-ALB disk (diameter : 1.2 cm) was implanted in the skin pocket made in a rat, and inoculated with Staphylococcus aureus or Staphylococcus epidermidis (0.1 ml of 108 CFU/ml). While all control grafts were infected at the time of removal, all LVFX-ALB Dacron grafts resisted infection, thus demonstrating their effectiveness. These studies suggest that LVFX controlled-releasing Dacron delivery system can decrease graft infection at the operated site.",
author = "Katsuhiro Fujimoto and Tsunehisa Sakurai and Keiko Yamamura and Takashi Osada and Tetsuo Hayashi and Kunihiko Koyasu and Toshitaka Nabeshima",
year = "1996",
month = "1",
day = "1",
doi = "10.2745/dds.11.345",
language = "English",
volume = "11",
pages = "345--349",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "5",

}

Fujimoto, K, Sakurai, T, Yamamura, K, Osada, T, Hayashi, T, Koyasu, K & Nabeshima, T 1996, 'The development of levofloxacin-bonded albumin dacron graft', Drug Delivery System, vol. 11, no. 5, pp. 345-349. https://doi.org/10.2745/dds.11.345

The development of levofloxacin-bonded albumin dacron graft. / Fujimoto, Katsuhiro; Sakurai, Tsunehisa; Yamamura, Keiko; Osada, Takashi; Hayashi, Tetsuo; Koyasu, Kunihiko; Nabeshima, Toshitaka.

In: Drug Delivery System, Vol. 11, No. 5, 01.01.1996, p. 345-349.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The development of levofloxacin-bonded albumin dacron graft

AU - Fujimoto, Katsuhiro

AU - Sakurai, Tsunehisa

AU - Yamamura, Keiko

AU - Osada, Takashi

AU - Hayashi, Tetsuo

AU - Koyasu, Kunihiko

AU - Nabeshima, Toshitaka

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The highly porous Dacron graft fabricated from polyester filaments is generally considered to be one of the most suitable synthetic vascular prostheses in arterial reconstructive surgery. To prevent blood leakage through the pores during an operation, several sealing materials such as albumin (ALB), collagen and gelatin have been employed. As vascular graft infection is a disastrous complication on vascular surgery, great effort must be taken to avoid it. To reduce the systemic effect while maintaining an increase in local resistance to graft infection, it seems reasonable that an antibiotic-loaded graft prolongs the release of antibiotics from the graft at the operated site. Common skin microorganisms, such as Staphylococcus aureus and Staphylococcus epidermidis, have been associated with graft-related infection. Levofloxacin (LVFX) was used as a model drug since it shows a broad protective spectrum against Gram-positive and Gram-negative bacteria, particularly staphylococci. To control the release rate of LVFX, ALB was bonded to the Dacron graft. In vitro and in vivo studies demonstrated that the release rate of LVFX decreased in the presence of ALB. One LVFX-ALB disk (diameter : 1.2 cm) was implanted in the skin pocket made in a rat, and inoculated with Staphylococcus aureus or Staphylococcus epidermidis (0.1 ml of 108 CFU/ml). While all control grafts were infected at the time of removal, all LVFX-ALB Dacron grafts resisted infection, thus demonstrating their effectiveness. These studies suggest that LVFX controlled-releasing Dacron delivery system can decrease graft infection at the operated site.

AB - The highly porous Dacron graft fabricated from polyester filaments is generally considered to be one of the most suitable synthetic vascular prostheses in arterial reconstructive surgery. To prevent blood leakage through the pores during an operation, several sealing materials such as albumin (ALB), collagen and gelatin have been employed. As vascular graft infection is a disastrous complication on vascular surgery, great effort must be taken to avoid it. To reduce the systemic effect while maintaining an increase in local resistance to graft infection, it seems reasonable that an antibiotic-loaded graft prolongs the release of antibiotics from the graft at the operated site. Common skin microorganisms, such as Staphylococcus aureus and Staphylococcus epidermidis, have been associated with graft-related infection. Levofloxacin (LVFX) was used as a model drug since it shows a broad protective spectrum against Gram-positive and Gram-negative bacteria, particularly staphylococci. To control the release rate of LVFX, ALB was bonded to the Dacron graft. In vitro and in vivo studies demonstrated that the release rate of LVFX decreased in the presence of ALB. One LVFX-ALB disk (diameter : 1.2 cm) was implanted in the skin pocket made in a rat, and inoculated with Staphylococcus aureus or Staphylococcus epidermidis (0.1 ml of 108 CFU/ml). While all control grafts were infected at the time of removal, all LVFX-ALB Dacron grafts resisted infection, thus demonstrating their effectiveness. These studies suggest that LVFX controlled-releasing Dacron delivery system can decrease graft infection at the operated site.

UR - http://www.scopus.com/inward/record.url?scp=85009576961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009576961&partnerID=8YFLogxK

U2 - 10.2745/dds.11.345

DO - 10.2745/dds.11.345

M3 - Article

AN - SCOPUS:85009576961

VL - 11

SP - 345

EP - 349

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 5

ER -

Fujimoto K, Sakurai T, Yamamura K, Osada T, Hayashi T, Koyasu K et al. The development of levofloxacin-bonded albumin dacron graft. Drug Delivery System. 1996 Jan 1;11(5):345-349. https://doi.org/10.2745/dds.11.345